anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a pure traditional Chinese medicine face pack which is made from the components by weight percentage of: 15 to 30 percent of japonica rice, 10 to 18 percent of angelica root, 10 to 18 percent of radix ampelopsis, 10 to 18 percent of Tuckahoe, 10 to 18 percent of common bletilla tuber, 2 to 5 percent of asarum, 2 to 5 percent of aconitum fischeri peichb and 9 to 20 percent of corn. All the components which are mixed according to the proportion are ground into powder of 80-200 meshes. When in use, the powder becomes pasty after being well mixed with egg white, honey and fruit juice, etc. and then can be directly daubed onto the face. By using the pure traditional Chinese medicine face pack, defects of speckle and fleck, melanin, lentigo, wrinkle, etc. on the face are eliminated, leading the skin of the face to be spotlessly white and ruddy; the pure traditional Chinese medicine face pack also has the effects of improving the metabolism of the facial skin, delaying senescence, reinforcing the natural luster of the skin, keeping the skin elasticity and promoting the whiteness of the skin, thus being suitable for long-term use as a skin care product.
Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type p53. Breast, ovarian, lung cancer and leukemia cells lines were treated with combinations of Akt activation inhibitor Triciribine (TCN) or Triciribine phosphate (TCNP) and chemotherapeutic drugs to determine the efficiency of combination therapy. Additionally, cells were introduced into xenograft models to determine in vivo effects of combination treatment. Combining TCN or TCNP with other anticancer drugs overcame cytotoxic or treatment resistance. Thus, TCN and TCNP are shown to broaden the spectrum of human tumors that can be effectively treated.
The efficacy of Focalin for the treatment of ADHD was established in two double-blind, parallel-group, placebo-controlled trials in untreated or previously treated patients (ages 6 to 17 years old) who met The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD inattentive, hyperactive-impulsive, or combined inattentive/hyperactive-impulsive subtypes. The sample was predominantly younger (ages 6 to 12 years); thus, the findings are most pertinent to this age group.

In Study 1, patients were randomized to receive either Focalin (5, 10, or 20 mg/day total dose), racemic methylphenidate HCl (10, 20, or 40 mg/day total dose), or placebo in a multicenter, 4-week, parallel group study in 132 pediatric patients. Patients received study medication twice daily separated by a 3.5 to 5.5 hours interval. Treatment was initiated with the lowest dose, and doses could be doubled at weekly intervals, depending on clinical response and tolerability, up to the maximum dose. The primary outcome was change from baseline to week 4 of the average score (an average of 2 ratings during the week) of the teacher’s version of the Swanson, Nolan and Pelham (SNAP)-ADHD Rating Scale. This 18 item scale measures ADHD symptoms of inattention and hyperactivity/impulsivity, rated on a scale of 0 (Not at All) to 3 (Very Much). Patients treated with Focalin showed a statistically significant improvement in symptom scores from baseline over patients who received placebo (Table 3).

    Abbreviations: ADHD, attention deficit hyperactivity disorder; SD, standard deviation; SNAP; swanson, Nolan and Pelham; n, number of patients available at the assessment time point.  
aAverage of two ratings.  
bStatistically significantly different from placebo. 

Study 2 was a multicenter, placebo-controlled, double-blind, 2-week treatment withdrawal study in 75 children (ages 6 to 12 years) who were responders during a 6-week, open-label initial treatment period. Children took study medication twice a day separated by a 3.5 to 5.5 hour interval. The primary outcome was proportion of treatment failures at the end of the 2-week withdrawal phase, where treatment failure was defined as a rating of 6 (much worse) or 7 (very much worse) on the Investigator Clinical Global Impression - Improvement (CGI-I). Patients continued on Focalin showed a statistically significant lower rate of failure over patients who received placebo (Table 4).

    Abbreviation: ADHD, attention deficit hyperactivity disorder.  
aOne patient did not have the value at Visit 10 and hence not included in this analysis.  
bStatistically significantly different from placebo.
Participants in this group will undergo 90-minute yoga sessions, 3 times per week, for 8 months. The yoga intervention includes a combination of asanas (postures), pranayama (breathing exercises), and meditation designed to improve flexibility, strength, and mental well-being.
Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise.
BACKGROUND: We created a multicenter survey for Italian orthopedic surgeons on how they approach leg length discrepancy (LLD) when dealing with primary total hip arthroplasty. Aim of the study was to show how surgeons manage LLD and follow the literature recommendations during clinical practice.
METHODS: The survey was composed of 25 questions divided into four sections: 1-surgeon's profile, 2-preoperative and 3-intraoperative evaluation, and 4-postoperative management. In this paper, we report results to answer Sects. 1 and 2. Absolute and relative frequencies of answers to Sects. 2 and 3 are reported. We divided the participants in subgroups based on the "surgeon's profile" and evaluated difference in the answers given.
RESULTS: Absolute and relative frequencies demonstrate low agreement among participants in all phases of LLD management. We demonstrated a statistically significant difference based on the surgeon's profile regarding these questions: radiographic measure of LLD depending on working experience, p = 0.008; digital planning based on surgeons' age, p < 0.001, and workplace, p = 0.026; intraoperative anatomical landmarks based on numbers of procedures per year, p = 0.020; and use of intraoperative X-rays based on working experience, p = 0.002.
CONCLUSIONS: LLD is a debated topic with no definitive recommendations. Many decisions still depend on tradition and surgeons' preference.
Daratumumab, carfilzomib, lenalidomide and dexamethasone are commonly used drugs for multiple myeloma. The efficacy of their combination has been proven in newly diagnosed multiple myeloma patients, including high-risk patients, while there are no relevant data in the Chinese population. Therefore, the efficacy of DKRd regimen in Chinese HR-NDMM patients needs to be further explored.

It is a prospective, single-arm study. High risk(HR)-NDMM Patients with will be recruited and their baseline data will be collected. Patients will be treated with bortezomib, lenalidomide and dexamethasone for the first cycle in order to urgently relieve bone pain, renal insufficiency, hypercalcemia and other symptoms, during which screening and evaluation is conducted. And then patients will be treated with 3 cycles of daratumumab, carfilzomib (K) lenalidomide (R) combined with dexamethasone (d), after which stem cells were collected from transplant-eligible, followed by autologous hematopoietic stem cell transplantation, two cycles of DKRD consolidation, DKR maintenance treatment for more than one year. If continuous MRD negativity for more than one year, patients will be treated with only lenalidomide maintenance. Transplant-noneligible patients will be treated with DKRD for 4-cycles consolidation therapy without transplantation, and then entered DKR maintenance therapy. If patients with continuous MRD negativity for more than one year will be treated with only lenalidomide maintenance. Follow-up was conducted and outcome indicators were collected to explore the efficacy and safety of DKRd treatment in HR-NDMM patients. The results of this study are expected to provide new treatment options and corresponding dosages for Chinese HR-NDMM patients, thereby improving patient outcomes and reducing the overall disease burden.
FIELD: immunobiotechnology. SUBSTANCE: method involves infection of cell culture with virus followed by its reproduction and inactivation, isolation, purification and sorption on viral antigen adjuvant. Cell culture is immobilized on collagen microcarrier at particle diameter 160-250 mcm and infected with tick-borne encephalitis virus at dose 5-30 LD 50 /cell. Antigen is isolated by sedimentation treatment at separation factor 7000-12000. For infection expediently to use diploid cells of human fetal lung culture or disaggregated culture of chicken embryo fibroblasts. EFFECT: improved method of vaccine preparing. 3 cl, 4 tbl
BACKGROUND: Computed tomography (CT) plays a great role in characterizing and quantifying changes in lung structure and function of chronic obstructive pulmonary disease (COPD). This study aimed to explore the performance of CT-based whole lung radiomic in discriminating COPD patients and non-COPD patients.
METHODS: This retrospective study was performed on 2785 patients who underwent pulmonary function examination in 5 hospitals and were divided into non-COPD group and COPD group. The radiomic features of the whole lung volume were extracted. Least absolute shrinkage and selection operator (LASSO) logistic regression was applied for feature selection and radiomic signature construction. A radiomic nomogram was established by combining the radiomic score and clinical factors. Receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA) were used to evaluate the predictive performance of the radiomic nomogram in the training, internal validation, and independent external validation cohorts.
RESULTS: Eighteen radiomic features were collected from the whole lung volume to construct a radiomic model. The area under the curve (AUC) of the radiomic model in the training, internal, and independent external validation cohorts were 0.888 [95% confidence interval (CI) 0.869-0.906], 0.874 (95%CI 0.844-0.904) and 0.846 (95%CI 0.822-0.870), respectively. All were higher than the clinical model (AUC were 0.732, 0.714, and 0.777, respectively, P < 0.001). DCA demonstrated that the nomogram constructed by combining radiomic score, age, sex, height, and smoking status was superior to the clinical factor model.
CONCLUSIONS: The intuitive nomogram constructed by CT-based whole-lung radiomic has shown good performance and high accuracy in identifying COPD in this multicenter study.
The purpose of this research study is to compare two different implant abutment designs, microgrooved and machined. The implant abutment is the dental prosthetic part that connects the implant to the crown. As a part of this study, subjects will have a dental implant surgically placed in their jaw bone. The implant will serve as the artificial root. After the implant heals, subjects will have the abutment and crown placed on the implant.

This study will compare levels of inflammation next to the implant abutment. Both implant abutment designs are FDA approved but differ in microtexturing. This study will determine if these texture differences have any impact on the healing of subjects' jaw bone and gums after implant surgery.
Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
Endometriosis is a chronic condition usually affecting women throughout their reproductive lives. It is defined as a growth of endometrial-like tissue (womb lining) outside the uterus (womb) and is associated with chronic pelvic pain that can be frequent and severe, resulting in tiredness, lower quality of life and difficulties in getting pregnant. Current treatments are unsatisfactory and there is an unmet need for new medical treatment for endometriosis. Research findings from our laboratory have shown that women with endometriosis have more lactate in their pelvis. In laboratory models of endometriosis, we have tested dichloroacetate (DCA), a compound used to treat metabolic disorders in children. Our results showed that DCA could stop the growth and survival of endometriosis cells and reduce lactate production. In our study we plan to investigate if we can we can recruit and retain women into a trial using this treatment. We will recruit 30 women aged 18 or over, with pelvic pain and a diagnosis of endometriosis within the last three years. Participants will complete informed consent, be willing to comply with the treatment and use contraception throughout the trial. We will recruit patients over six months at Royal Infirmary of Edinburgh. Women who consent will take a daily dose of DCA capsules for 12 weeks.
Voriconazole has been associated with photosensitivity skin reaction. Patients, including pediatric patients, should avoid exposure to direct sunlight during voriconazole treatment and should use measures such as protective clothing and sunscreen with high sun protection factor (SPF). If phototoxic reactions occur, the patient should be referred to a dermatologist and voriconazole discontinuation should be considered. If voriconazole is continued despite the occurrence of phototoxicity-related lesions, dermatologic evaluation should be performed on a systematic and regular basis to allow early detection and management of premalignant lesions. Squamous cell carcinoma of the skin (including cutaneous SCC in situ, or Bowen’s disease) and melanoma have been reported during long-term voriconazole therapy in patients with photosensitivity skin reactions. If a patient develops a skin lesion consistent with premalignant skin lesions, squamous cell carcinoma or melanoma, voriconazole should be discontinued. In addition, voriconazole has been associated with photosensitivity related skin reactions such as pseudoporphyria, cheilitis, and cutaneous lupus erythematosus, as well as increased risk of skin toxicity with concomitant use of methotrexate, a drug associated with ultraviolet (UV) reactivation. There is the potential for this risk to be observed with other drugs associated with UV reactivation. Patients should avoid strong, direct sunlight during voriconazole therapy.

The frequency of phototoxicity reactions is higher in the pediatric population. Because squamous cell carcinoma has been reported in patients who experience photosensitivity reactions, stringent measures for photoprotection are warranted in children. In children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.
The invention discloses a method for expelling a bacillus anthracis virulence large plasmid pXO1. A recombinant vector provided in the invention is a vector acquired by inserting DNA molecules into a Sma1 locus of a shuttle plasmid pKSV7, and a nucleotide sequence of the DNA molecules is a sequence 1 of a sequence table. Experiments in the invention prove that the method constructs an incompatible plasmid based on a plasmid exclusion principle, that the incompatible plasmid specifically expels the virulence large plasmid pXO1 from a bacillus anthracis A16R (pXO1+pXO2-), that the obtained product is cultivated at 37 DEG C and introduced exogenous plasmids are expelled, and that a bacterial strain A16RO is obtained to expel the pXO1. The method has characteristics of simplicity, fast speed, good specificity, and high safety. The method is of great significance for construction of bacillus anthracis plasmid-lacking stains and a research on interactions between the large plasmid pXO1 and chromosomes. The method provides new experimental means for constructing new vaccine strains and new ideas for preventing and curing the bacillus anthracis.
The invention discloses a tumor cell actively targeted drug delivery system. The drug delivery system comprises the following component contents (by weight): 100-200 parts of bovine serum albumin, 200-400 parts of folic acid, 0.05-0.10 part of 25% glutaral pentanedial, 0.005-0.01 part of alcohol, 5-15 parts of anhydrous dimethyl sulphoxide, 80-100 parts of dicyclohexylcarbodiimide, 70-80 parts of N-hydroxysuccinimide, 0.4-0.6 part of tri-ethylamine, 100-200 parts of anhydrous acetone, 100-200 parts of ether, and 50-100 parts of polybutylene succinate. The drug delivery system comprises preparation steps of activated folate ester, folic acid-bovine serum albumin and colloid suspension. The drug delivery system has low toxicity to normal tissues while killing tumor cells with high-expression of folate receptors; and the folic acid has low immunogenicity, convenient modification and simple storage. The drug delivery system has the advantages of needing short time to reach targets and clearing blood quickly; has obvious advantages in tumor chemotherapy. The invention further discloses a preparation method and application of the tumor cell actively targeted drug delivery system.
MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
Excess dietary salt causes target organ damage and increases the risk for adverse cardiovascular (CV) events independent of blood pressure (BP). Recent data in salt-resistant, normotensive rodents suggest that high dietary salt enhances the excitability or gain of sympathetic circuits, exaggerates sympathetic and CV responses to various stimuli, and increases BP variability (BPV). There are limited data regarding the impact of dietary salt intake on sympathetic nerve activity (SNA) and CV function in salt-resistant humans as well as the underlying mechanisms contributing to these adverse effects. The long-term goal is to determine how dietary salt adversely affects BP regulation and CV health. The objective of this proposal is to comprehensively evaluate the impact of dietary salt intake on SNA and CV reactivity and BPV in normotensive humans. The investigators have 2 specific aims: 1) Aim 1 will test the hypothesis that high dietary salt increases SNA and CV reactivity in normotensive adults, 2) Aim 2 will test the hypothesis that high dietary salt increases BPV in normotensive adults. The expected outcome is to demonstrate that dietary salt loading increases CV reactivity and BPV through a sympathetic nervous system mechanism that originates in the brain. The proposed research is significant, as these studies will provide empirical evidence that dietary salt intake impacts neurohumoral control of the circulation in salt-resistant humans. The proposed research is innovative because it will identify a novel neurogenic action of dietary salt in human CV regulation.
The invention discloses a medicine for treating perimenopause syndrome. The medicine is a medicament prepared by the following raw materials in parts according to the proportion by weight: 225-275 parts of herba leonuri, 225-275 parts of glossy privet fruit, 70-100 parts of plocamium telfairiae, 70-100 parts of phellinus igniarius and 70-100 parts of fructus corni. The formulation of the medicine is any formulation suitable for oral administration, such as oral liquid, capsules, tablets, pills or granules. The medicine for treating perimenopause syndrome disclosed by the invention has main efficacies of nourishing yin and tonifying yang, coordinating heart-kidney, soothing liver and resolving depression and soothing nerves and relieving restlessness, has the efficacies of improving various syndromes of female perimenopause and regulating hormone level, and has no toxic or side effects. Observed by clinical long-time administration, the medicine has no toxic or side effect to heart, liver, kidney and bone marrow haematopoietic function. The medicine is reasonable in prescription, extract in efficacy, safe and reliable, easy to obtain and low in cost, and therefore, the medicine is worthy of clinical popularization and application.
Fibrosis is characterized by excessive extracellular matrix (ECM) deposition resulting from dysregulated wound healing and connective tissue repair mechanisms. Excessive accumulation of ECM leads to fibrous tissue formation, impairing organ function and driving the progression of various fibrotic diseases. Recently, the role of small ubiquitin-like modifiers (SUMO) in fibrotic diseases has attracted significant attention. SUMO-mediated SUMOylation, a highly conserved posttranslational modification, participates in a variety of biological processes, including nuclear-cytosolic transport, cell cycle progression, DNA damage repair, and cellular metabolism. Conversely, SUMO-specific proteases cleave the isopeptide bond of SUMO conjugates, thereby regulating the deSUMOylation process. Mounting evidence indicates that SUMOylation and deSUMOylation regulate the functions of several proteins, such as Smad3, NF-κB, and promyelocytic leukemia protein, which are implicated in fibrotic diseases like liver fibrosis, myocardial fibrosis, and pulmonary fibrosis. This review summarizes the role of SUMO in fibrosis-related pathways and explores its pathological relevance in various fibrotic diseases. All evidence suggest that the SUMO pathway is important targets for the development of treatments for fibrotic diseases.
Techniques for delivering data for coordinating multiple party use of a facility include producing conditions data by measuring without human intervention current condition of a facility that is used by multiple human parties. Availability data that indicates present or future availability for the facility is generated based at least in part on the conditions data. Coordination data based at least in part on the availability data is presented for the parties. These techniques allow rapid dynamic adaptation to changing status of a high-value facility while being less reliant on varied and subjective human motivations for reporting status changes. Undue exposure of sensitive information can be avoided by deriving less detailed views from high-resolution images of the facility and its users. Coordination data can be projected directly onto, and manual input can be derived from, a magnetic white board currently used for coordination at many facilities.